I am surprised -- and happily so -- that the filing of the FDA New Drug Application is only weeks away, now. I was a little concerned that it would slip into 2011. Merck should be very chastened by this Telaprevir® news, by the way. Here is a salient bit of the Reuters reporting:
. . . .Vertex. . . said it plans to seek U.S. approval for the medicine [Telaprevir] in coming weeks. . . .
Telaprevir, from a new class of hepatitis C treatments, is an antiviral drug that is expected to compete with a similar medicine being developed by Merck, called boceprevir. But analysts have been virtually unanimous in their belief that telaprevir is the superior medicine.
Merck has completed phase III trials. . . .
No doubt. It is good to see the unanimity set in stone, by the MSM (as we've long foretold). And importantly, more than one analyst is now calling Telaprevir a $4 billion a year drug -- when it really gets rolling. It is, effectively, a cure for Hep C.